'Painkillers Market Will Reach $61.6 Billion in 2012' Visiongain Report Predicts

LONDON, September 6, 2012 /PRNewswire/ --

A new report by visiongain predicts that the world market for drugs to relieve pain will reach $61.6 billion for 2012. That revenue forecast appears in World Pain Relieving Drug Market 2012-2022, published in September 2012. Visiongain is a business information provider based in London, UK.

The study forecasts that the overall market for pain relieving drugs will grow steadily from 2012 to 2022. The world pain-treating drug market is a high-revenue industry with a high public and healthcare profile. Market growth will be stimulated by rises in disease prevalence, ageing populations and prevalence of cancer, arthritis and diabetes.

Growth of the pain treatment market will be stimulated by new drugs and reformulations of existing products from 2012 onwards. The launch of new treatments, including more-efficacious drugs, improved drug delivery and new dosing schedules, will increase revenues. Visiongain believes that increasing public awareness and the development of submarkets such as neuropathic and cancer pain treatment will be crucial to expansion of the industry and market.

Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: "Pain is a prevalent condition with huge socio-economic consequences. Many people need pain relief to complete everyday tasks. To achieve more-efficient pain relief, a better understanding of its underlying mechanisms and causes are needed, which, in turn, will lead to more pain therapies being tailored to a specific pain type. The high growth rate of the neuropathic pain market is a good example. Also, drug approvals for neuropathic indications are becoming more frequent. Importantly, the pharma industry has many promising R&D pipeline candidates for pain relief."

Visiongain's report shows revenue forecasts to 2022 at overall world market, submarket, product and national level. The study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines. It forecasts these world-level submarkets:

• Narcotics
• Non-narcotics
• Neuropathic pain relievers
• Treatments for migraines
• Treatments for arthritis.

The investigation predicts revenues of 28 leading drugs in the painkillers market, including Oxycontin ER, Panadol, Lyrica and Zomig. Research, data and analyses cover activities of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other pharmaceutical companies.

That report discusses R&D and commercial news, shows research interviews and forecasts revenues in leading national markets. The work analyses the US, Japan, five leading EU countries (the EU5), India and China.

World Pain Relieving Drug Market 2012-2022 adds to visiongain's range of analytical reports on industries and markets in healthcare.
 

For sample pages, an exec summary and further information concerning the World Pain Relieving Drug Market 2012-2022 please visit: http://www.visiongain.com/Report/867/World-Pain-Relieving-Drug-Market-2012-2022

Companies listed in the report include:
Companies Listed
AB Science
Abbott Laboratories
AcelRx Pharmaceuticals
Actavis
Acura Pharmaceuticals
Allergan
Almirall
Alpharma
ALZA Corporation
American Council for Headache Education
Amgen
Anesiva
Aoxing Pharmaceuticals
Apotec
Apotex
Arcion Therapeutics
Astellas Pharma
AstraZeneca
Avanir Pharmaceuticals
Bayer
BioDelivery Sciences
Biogen Idec
Biovail Corporation
Bristol-Myers Squibb
Britannia Pharmaceuticals
CeNeS Pharmaceuticals
Centocor Ortho Biotech
China Aoxing
CK Life Sciences
Collegium Pharmaceutical
CoLucid Pharmaceuticals
Dainippon
Dara Biosciences
Depomed
Descartes Therapeutics
Dr. Reddy's Laboratories
Durect
Eisai
Eli Lilly
Endo Pharmaceuticals
EpiCept
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Forest Pharmaceuticals
Galderma
Genentech
Genmab
GlaxoSmithKline (GSK)
Grünenthal
Horizon Pharma
Human Genome Sciences
Insys Therapeutics
International Association for the Study of Pain (IASP)
Ipsen
IVAX Pharmaceuticals
Janssen Pharmaceuticals
Johns Hopkins University
Johnson and Johnson (J&J)
King Pharmaceuticals
Ligand Pharmaceuticals
Lundbeck
MAP Pharmaceuticals
Merck & Co.
Merck Serono
Mitsubishi Tanabe Pharma
Mylan
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
Nektar Therapeutics
NeurAxon
NeurogesX
Neurotune
Newron Pharmaceuticals
NicOx Pharmaceuticals
Novartis
NuPathe
Nuvo Research
Omeros
Ono Pharmaceutical
Organon
Ortho-McNeil
Pacira Pharmaceuticals
Pain Therapeutics
Paion
Par Pharmaceuticals
Penwest
Pfizer
Pharmacia
PLx Pharma
Pozen
PriCara Pharmaceuticals
Procter & Gamble
Proteus
Purdue Pharma
QRxPharma
Ranbaxy
Ratiopharm
Rigel Pharmaceuticals
Roche
Schering Plough
Shire
SkyePharma
Solvay Pharmaceuticals
Spinifex Pharmaceuticals
Stada Pharmaceuticals
Sun Pharmaceuticals
Syntaxin
Takeda
Teikoku
Teva Pharmaceutical Industries
The Arthritis Foundation
The International Diabetes Federation (IDF)
The Neuropathy Association
The World Health Organization (WHO)
UCB
University of Queensland
US Census Bureau
US Society for Neuroscience
US WorldMeds
Valeant Pharmaceuticals International
Watson Pharmaceuticals
WEX Pharmaceuticals
Wyeth (now part of Pfizer)
Xenoport
Zars Pharmaceuticals
Zenyaku Kogyo
Zogenix 

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44-(0)-207-336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

For an executive summary of this report or to order it today please contact: Email: Sara Peerun on sara.peerun@visiongainglobal.com, Tel: +44(0)20-7336-6100